Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
61,818.68 +2,430.55 (+4.09%) CMC Crypto 200
1,341.26 +64.28 (+5.03%)
Relay Therapeutics, Inc. (RLAY)
| Previous close | 7.08 |
| Open | 8.71 |
| Bid | 7.00 x 100 |
| Ask | 7.08 x 100 |
| Day's range | 6.79 - 8.71 |
| 52-week range | 5.70 - 13.32 |
| Volume | |
| Avg. volume | 1,236,927 |
| Market cap | 930.461M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.79 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.05 |
GuruFocus.comRelay Therapeutics Outperforms Revenue Expectations in Q1 2024
Despite Net Loss, Relay Therapeutics Reports Significant Revenue Growth and Robust Pipeline Progress
ZacksRelay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 11.43% and 2,905.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireRelay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2024 financial results and corporate highlights. “We have started 2024 with a focus
